Raymond James Financial Services Advisors’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | $584K | Buy |
5,070
+2,757
| +119% | +$318K | ﹤0.01% | 2506 |
|
|
2024
Q2 | $318K | Buy |
+2,313
| New | +$318K | ﹤0.01% | 2831 |
|
|
2024
Q1 | – | Sell |
-8,201
| Closed | -$1.08M | – | 3441 |
|
|
2023
Q4 | $1.08M | Sell |
8,201
-5,444
| -40% | -$717K | ﹤0.01% | 1929 |
|
|
2023
Q3 | $1.54M | Sell |
13,645
-881
| -6% | -$99.1K | ﹤0.01% | 1648 |
|
|
2023
Q2 | $1.37M | Buy |
14,526
+104
| +0.7% | +$9.81K | ﹤0.01% | 1748 |
|
|
2023
Q1 | $1.46M | Buy |
14,422
+884
| +7% | +$89.5K | ﹤0.01% | 1669 |
|
|
2022
Q4 | $1.62M | Buy |
13,538
+8,962
| +196% | +$1.07M | ﹤0.01% | 1562 |
|
|
2022
Q3 | $486K | Buy |
+4,576
| New | +$486K | ﹤0.01% | 2262 |
|
|
2018
Q4 | – | Sell |
-1,917
| Closed | -$236K | – | 2695 |
|
|
2018
Q3 | $236K | Buy |
+1,917
| New | +$236K | ﹤0.01% | 2424 |
|